Evidence map›Paper›PMID 25334026›Full record

ArticlePloS one2014

Near-infrared imaging of adoptive immune cell therapy in breast cancer model using cell membrane labeling.

Fatma M Youniss, Gobalakrishnan Sundaresan, Laura J Graham, Li Wang, Collin R Berry, Gajanan K Dewkar, Purnima Jose, Harry D Bear, Jamal Zweit

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 36 citations in OpenAlex.

  1. Recent advances in non-invasiveBiomaterials science · 2025
    Review
  2. Review
  3. Article
  4. Cancer therapy in mice using a pure population of CD8Cancer immunology, immunotherapy : CII · 2021
    Article
  5. Article
  6. Near-infrared fluorescence imaging in immunotherapy.Advanced drug delivery reviews · 2020
    Review
  7. Article
  8. New Developments in Imaging Cell-Based Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Review
  9. Dendritic cell trafficking in tumor-bearing mice.Cancer immunology, immunotherapy : CII · 2018
    Article
  10. TricarbocyanineChemical science · 2018
    Article
  11. Article
  12. The Immunoimaging Toolbox.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Advances in Molecular Imaging Strategies forBioMed research international · 2016
    Review
  19. Imaging Biomarkers in Immunotherapy.Biomarkers in cancer · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Fatma M YounissDepartment of Radiology, Center for Molecular Imaging, Virginia Commonwealth University, Richmond, Virginia, United States of America.
Gobalakrishnan SundaresanDepartment of Radiology, Center for Molecular Imaging, Virginia Commonwealth University, Richmond, Virginia, United States of America.
Laura J GrahamDepartment of Surgery, Division of Surgical Oncology, Virginia Commonwealth University, Richmond, Virginia, United States of America.
Li WangDepartment of Radiology, Center for Molecular Imaging, Virginia Commonwealth University, Richmond, Virginia, United States of America.
Collin R BerryDepartment of Radiology, Center for Molecular Imaging, Virginia Commonwealth University, Richmond, Virginia, United States of America.
Gajanan K DewkarDepartment of Radiology, Center for Molecular Imaging, Virginia Commonwealth University, Richmond, Virginia, United States of America.
Purnima JoseDepartment of Radiology, Center for Molecular Imaging, Virginia Commonwealth University, Richmond, Virginia, United States of America.
Harry D BearDepartment of Surgery, Division of Surgical Oncology, Virginia Commonwealth University, Richmond, Virginia, United States of America; Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, United States of America.
Jamal ZweitDepartment of Radiology, Center for Molecular Imaging, Virginia Commonwealth University, Richmond, Virginia, United States of America; Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, United States of America.
Virginia Commonwealth University · US

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kim Felder Rhoads · 1985 to 2026
$51.0M
NCI NIH HHS P30 CA016059
6 · The paper itself

Abstract

The overall objective of this study is to non-invasively image and assess tumor targeting and retention of directly labeled T-lymphocytes following their adoptive transfer in mice. T-lymphocytes obtained from draining lymph nodes of 4T1 (murine breast cancer cell) sensitized BALB/C mice were activated in-vitro with Bryostatin/Ionomycin for 18 hours, and were grown in the presence of Interleukin-2 for 6 days. T-lymphocytes were then directly labeled with 1,1-dioctadecyltetramethyl indotricarbocyanine Iodide (DiR), a lipophilic near infrared fluorescent dye that labels the cell membrane. Assays for viability, proliferation, and function of labeled T-lymphocytes showed that they were unaffected by DiR labeling. The DiR labeled cells were injected via tail vein in mice bearing 4T1 tumors in the flank. In some cases labeled 4T1 specific T-lymphocytes were injected a week before 4T1 tumor cell implantation. Multi-spectral in vivo fluorescence imaging was done to subtract the autofluorescence and isolate the near infrared signal carried by the T-lymphocytes. In recipient mice with established 4T1 tumors, labeled 4T1 specific T-lymphocytes showed marked tumor retention, which peaked 6 days post infusion and persisted at the tumor site for up to 3 weeks. When 4T1 tumor cells were implanted 1-week post-infusion of labeled T-lymphocytes, T-lymphocytes responded to the immunologic challenge and accumulated at the site of 4T1 cell implantation within two hours and the signal persisted for 2 more weeks. Tumor accumulation of labeled 4T1 specific T-lymphocytes was absent in mice bearing Meth A sarcoma tumors. When lysate of 4T1 specific labeled T-lymphocytes was injected into 4T1 tumor bearing mice the near infrared signal was not detected at the tumor site. In conclusion, our validated results confirm that the near infrared signal detected at the tumor site represents the DiR labeled 4T1 specific viable T-lymphocytes and their response to immunologic challenge can be imaged in vivo.

Indexed as

AnimalsBreast NeoplasmsCarbocyaninesCell Line, TumorCell MembraneCell SurvivalCell TrackingDisease Models, AnimalFemaleImmunohistochemistryImmunotherapy, AdoptiveInterferon-gammaInterleukin-2IonomycinLymphocyte ActivationMice3,3'-dioctadecylindocarbocyanineCarbocyaninesInterferon-gammaInterleukin-2Ionomycin

Identifiers

PMID25334026
PMCPMC4204826
OpenAlexW1984035300

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.